Immatics IMTX
NASDAQ IMTX
$9.56 +0.10 (+1.06%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2026)

Immatics (IMTX) posted Liabilities and Shareholders Equity of $654.6 million for Q4 2025, up 7.98% sequentially from $606.2 million in Q3 2025, and down 12.01% YoY from $743.9 million in Q4 2024.

Analysis

Immatics (IMTX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Immatics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $654.6 million in Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 12.01% year-over-year to $654.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 billion (down 6.68% YoY) and the FY2025 annual result came in at $635.3 million, down 15.68% from the prior year.
  • Liabilities and Shareholders Equity rose to $654.6 million in Q4 2025 per IMTX's latest filing, from $606.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $743.9 million in Q4 2024 and troughed at $199.8 million in Q4 2021.
  • A 5-year average of $484.2 million and a median of $461.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 119.32% in 2021, down 34.2% in 2021.
  • Over 5 years, Liabilities and Shareholders Equity stood at $199.8 million in 2021, then surged by 108.26% to $416.1 million in 2022, then surged by 31.87% to $548.7 million in 2023, then soared by 35.58% to $743.9 million in 2024, then decreased by 12.01% to $654.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $654.6 million, $606.2 million, and $642.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Immatics 1.17 Bn 711.21 Mn - 564.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 564.60 Mn
Mar 31, 2026 636.02 Mn
Dec 31, 2025 654.58 Mn
Sep 30, 2025 606.22 Mn
Jun 30, 2025 642.16 Mn
Mar 31, 2025 674.99 Mn
Dec 31, 2024 743.90 Mn
Sep 30, 2024 633.93 Mn
Jun 30, 2024 675.17 Mn
Mar 31, 2024 709.53 Mn
Dec 31, 2023 548.69 Mn
Sep 30, 2023 476.20 Mn
Jun 30, 2023 446.66 Mn
Mar 31, 2023 406.25 Mn
Dec 31, 2022 416.08 Mn
Sep 30, 2022 357.22 Mn
Jun 30, 2022 393.00 Mn
Mar 31, 2022 316.70 Mn
Dec 31, 2021 199.79 Mn
Sep 30, 2021 234.57 Mn